ClinicalTrials.gg
CompletedNCT04745221Updated Oct 26, 2026

Efficacy and Safety of Auto-FMT in Preventing aGVHD

An interventional study of Auto-FMT with Standard Prophylaxis and Standard Prophylaxis in Graft Versus Host Disease, Acute, sponsored by The First Affiliated Hospital of Soochow University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 26, 2026Now CompletedStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.

Enrollment
26th of 72
105 · median 53
Started
2021
with 8 others
No phase
16 of 81
6 open now
Registered
33rd of 81
by date
Lead sponsor
7 of 81
The First Affiliated Hospital of Soochow University

Among the 81 studies in Graft vs Host Disease with a site in China, this one is the 26th largest by enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2021, is one of 16 with no phase, and was the 33rd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Graft vs Host Disease with a site in China, or all of them as a file.
02

Study summary

To evaluation the efficacy and safety of autologous fecal microbiota transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation.

03

Conditions studied

  • Graft Versus Host Disease, Acute

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 60 years, inclusive.
  2. Patients with hematologic indicated for Haplo-.
  3. Candidate for myeloablative conditioning and standard prophylaxis consisting of CsA,MTX, MMF and ATG.
  4. (ECOG) performance status 0, 1, or 2.
  5. Absence of severe end-organ dysfunction, defined as but not limited to:

    • Adequate cardiac function: (LVEF) ≥50%;
    • Adequate hepatic function: serum total ≤34 µmol/L, (AST) and alanine aminotransferase (ALT) \< 2 × (ULN);
    • Adequate renal function: serum creatinine ≤130 µmol/L.
  6. Estimated survival of at least 3 months.
  7. Meet the criteria for autologous fecal microbiota collection:

    • No active infection caused by multidrug-resistant (MDR) organisms, and no MDR organism colonization;
    • No intake of probiotics or prebiotics within 1 month before fecal microbiota collection;
    • No pre-existing chronic gastrointestinal disorders;
    • No laboratory abnormalities suggestive of active infection, including screening tests such as procalcitonin (PCT), viral hepatitis serology, T-SPOT, syphilis serology, and (HIV) testing.
  8. Able to understand study procedures and voluntarily provide written ; willing and able to adhere to study treatment and follow-up requirements.

Exclusion criteria

Exclusion Criteria

  1. Prior history of hematopoietic cell transplantation or allogeneic hematopoietic stem cell transplantation.
  2. Prior documented infection with multidrug-resistant (MDR) organisms.
  3. Presence of any medical condition that would interfere with study procedures or place the patient at high risk of serious complications, including but not limited to:

    • Severe cardiac dysfunction ( [LVEF] \< 50%);
    • Abnormal hepatic function: serum total > 34 µmol/L, (AST) and alanine aminotransferase (ALT) ≥ 2 × (ULN);
    • Abnormal renal function: serum creatinine > 130 µmol/L.
  4. Known intolerance to auto-FMT.
  5. Failure to satisfy criteria for post-HSCT FMT administration, defined by any of the following:

    • Failure to achieve hematopoietic reconstitution after HSCT;
    • Onset of established acute (aGVHD) prior to auto-FMT;
    • Uncontrolled active infection;
    • Concurrent cytomegalovirus (CMV) or Epstein-Barr virus (EBV) reactivation;
    • Clinical conditions that preclude tolerance to auto-FMT, including prominent nausea, vomiting, abdominal pain, diarrhea, intestinal obstruction, gastrointestinal bleeding.
  6. Pregnant or lactating individuals.
  7. Dementia or altered mental status that impairs the capacity to provide .
  8. Any condition deemed by the investigator to place the patient or study results at unnecessary risk.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Auto-FMT Group

    Haplo-HSCT patients will receive autologous fecal microbiota capsules with standard prophylaxis regimen for GVHD after HSCT.

    Other: Auto-FMT with Standard Prophylaxis

  • Active comparator
    Standard Group

    Haplo-HSCT patients will receive standard prophylaxis regimen for GVHD after HSCT.

    Drug: Standard Prophylaxis

Interventions

  • OtherAuto-FMT with Standard Prophylaxis

    Autologous fecal microbiota capsules will be administered orally in divided doses post-engraftment with Standard prophylaxis regimen for GVHD after HSCT.

    Also known as: Cyclosporine(CsA), Methotrexate(MTX), Mycophenolate mofetil(MMF), Anti-thymocyte globulin(ATG)

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard prophylaxis regimen for GVHD after HSCT, including CsA,MTX, MMF and ATG.

    Also known as: Cyclosporine(CsA), Methotrexate(MTX), Mycophenolate mofetil(MMF), Anti-thymocyte globulin(ATG)

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of grade II-IV aGVHD

    Estimated cumulative incidence of grade II-IV aGVHD.

    Time frame: 100 days after HSCT.

Secondary outcomes

  1. Cumulative incidence of grade Ill-IV aGVHD

    Estimated cumulative incidence of grade Ill-IV aGVHD.

    Time frame: 100 days after HSCT.

  2. Cumulative incidence of chronic graft-versus-host disease(cGVHD)

    Estimated cumulative incidence of cGVHD.

    Time frame: 1 year after HSCT.

  3. Overall survival

    Estimated overall survival.

    Time frame: 1 year after HSCT.

  4. Graft-versus-host disease-free relapse-free survival(GRFS)

    Estimated GRFS.

    Time frame: 1 year after HSCT.

  5. Cumulative incidence of relapse

    Estimated cumulative incidence of relapse.

    Time frame: 1 year after HSCT.

  6. Non-Relapse Mortality(NRM)

    Estimated NRM.

    Time frame: 1 year after HSCT.

  7. Relapse-free survival (RFS)

    Estimated RFS.

    Time frame: 1 year after HSCT.

  8. Grade 3 or higher adverse events

    Number of unique patients who had an adverse event that was graded 3 or greater.

    Time frame: Up to 100 days.

07

Study locations

1 site
  • First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Aug 2025, 48 months.

Of 32 interventional studies with no phase under Graft vs Host Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 89. This study's 48 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Mar 2021 → Aug 2021, primary completion Mar 2027 → Aug 2025 and completion Mar 2027 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 9, 2021
StartActual
Aug 27, 2021was Mar 2021
Primary completionActual
Aug 27, 2025was Mar 2027
CompletionActual
May 19, 2026was Mar 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • First Affiliated Hospital of Soochow University · Suzhou, China
Show 1 removed
  • Ye Zhao · Suzhou, China
Oct 26, 2026
Start date
Mar 1, 2021→Aug 27, 2021
Oct 26, 2026
Primary completion
Mar 1, 2027→Aug 27, 2025 (actual)
Oct 26, 2026
Study completion
Mar 1, 2027→May 19, 2026 (actual)
Oct 26, 2026
Enrollment
100 (estimated)→105 (actual)
Oct 26, 2026
Eligibility
Criteria largely rewritten (33 changes)
What changed in the criteria
Inclusion criteria
  • RemovedHaplo-HSCT patients; Bacteroidetes >0.1%; inverse Simpson diversity ≥2
  • AddedAge between 18 and 60 years, inclusive.
  • AddedPatients with hematologic malignancies indicated for Haplo-HSCT.
  • AddedCandidate for myeloablative conditioning and standard GVHD prophylaxis consisting of CsA,MTX, MMF and ATG.
  • AddedEastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  • AddedAbsence of severe end-organ dysfunction, defined as but not limited to:
  • AddedAdequate cardiac function: left ventricular ejection fraction (LVEF) ≥50%;
  • AddedAdequate hepatic function: serum total bilirubin ≤34 µmol/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × upper limit of normal (ULN);
  • AddedAdequate renal function: serum creatinine ≤130 µmol/L.
  • AddedEstimated survival of at least 3 months.
  • AddedMeet the criteria for autologous fecal microbiota collection:
  • AddedNo active infection caused by multidrug-resistant (MDR) organisms, and no MDR organism colonization;
  • AddedNo intake of probiotics or prebiotics within 1 month before fecal microbiota collection;
  • AddedNo pre-existing chronic gastrointestinal disorders;
  • AddedNo laboratory abnormalities suggestive of active infection, including screening tests such as procalcitonin (PCT), viral hepatitis serology, T-SPOT, syphilis serology, and human immunodeficiency virus (HIV) testing.
  • AddedAble to understand study procedures and voluntarily provide written informed consent; willing and able to adhere to study treatment and follow-up requirements.
Exclusion criteria
  • RemovedGastrointestinal diseases;Age>60; or Age<10;Probiotics or prebiotics were taken before enrollment
  • AddedPrior history of autologous hematopoietic cell transplantation or allogeneic hematopoietic stem cell transplantation.
  • AddedPrior documented infection with multidrug-resistant (MDR) organisms.
  • AddedPresence of any medical condition that would interfere with study procedures or place the patient at high risk of serious complications, including but not limited to:
  • AddedSevere cardiac dysfunction (left ventricular ejection fraction [LVEF] < 50%);
  • AddedAbnormal hepatic function: serum total bilirubin > 34 µmol/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN);
  • AddedAbnormal renal function: serum creatinine > 130 µmol/L.
  • AddedKnown intolerance to auto-FMT.
  • AddedFailure to satisfy criteria for post-HSCT FMT administration, defined by any of the following:
  • AddedFailure to achieve hematopoietic reconstitution after HSCT;
  • AddedOnset of established acute graft-versus-host disease (aGVHD) prior to auto-FMT;
  • AddedUncontrolled active infection;
  • AddedConcurrent cytomegalovirus (CMV) or Epstein-Barr virus (EBV) reactivation;
  • AddedClinical conditions that preclude tolerance to auto-FMT, including prominent nausea, vomiting, abdominal pain, diarrhea, intestinal obstruction, gastrointestinal bleeding.
  • AddedPregnant or lactating individuals.
  • AddedDementia or altered mental status that impairs the capacity to provide informed consent.
  • AddedAny condition deemed by the investigator to place the patient or study results at unnecessary risk.
Oct 26, 2026
Interventions
Added Auto-FMT with Standard Prophylaxis·Drug: Standard Prophylaxis; removed autologous fecal bacteria. Arm changed with auto-FMT→Auto-FMT Group. Arms added: Standard Group; arms removed: empty capsule
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Acute Graft-Versus-Host DiseaseNow Cumulative incidence of grade II-IV aGVHDTime frame: 90 days after haploidentical hematopoietic stem cell transplantation → 100 days after HSCT.
Oct 26, 2026
Secondary outcomes
1 edited, 7 added, 1 removed
What changed in the outcomes
  • EditedoverallOverall survivalTime frame: 90 days after haploidentical hematopoietic stem cell transplantation → 1 year after HSCT.
  • AddedCumulative incidence of grade Ill-IV aGVHDTime frame: 100 days after HSCT.
  • AddedCumulative incidence of chronic graft-versus-host disease(cGVHD)Time frame: 1 year after HSCT.
  • AddedGraft-versus-host disease-free relapse-free survival(GRFS)Time frame: 1 year after HSCT.
  • AddedCumulative incidence of relapseTime frame: 1 year after HSCT.
  • AddedNon-Relapse Mortality(NRM)Time frame: 1 year after HSCT.
  • AddedRelapse-free survival (RFS)Time frame: 1 year after HSCT.
  • AddedGrade 3 or higher adverse eventsTime frame: Up to 100 days.
  • RemovedEvent free survivalTime frame: 90 days after haploidentical hematopoietic stem cell transplantation
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • First Affiliated Hospital of Soochow University · Suzhou, China
    Show 1 removed
    • Ye Zhao · Suzhou, China
    Start date Mar 1, 2021→Aug 27, 2021
    Primary completion Mar 1, 2027→Aug 27, 2025 (now actual)
    Study completion Mar 1, 2027→May 19, 2026 (now actual)
    Enrollment 100 (estimated)→105 (actual)
    Eligibility Criteria largely rewritten (33 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedHaplo-HSCT patients; Bacteroidetes >0.1%; inverse Simpson diversity ≥2
    • AddedAge between 18 and 60 years, inclusive.
    • AddedPatients with hematologic malignancies indicated for Haplo-HSCT.
    • AddedCandidate for myeloablative conditioning and standard GVHD prophylaxis consisting of CsA,MTX, MMF and ATG.
    • AddedEastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
    • AddedAbsence of severe end-organ dysfunction, defined as but not limited to:
    • AddedAdequate cardiac function: left ventricular ejection fraction (LVEF) ≥50%;
    • AddedAdequate hepatic function: serum total bilirubin ≤34 µmol/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × upper limit of normal (ULN);
    • AddedAdequate renal function: serum creatinine ≤130 µmol/L.
    • AddedEstimated survival of at least 3 months.
    • AddedMeet the criteria for autologous fecal microbiota collection:
    • AddedNo active infection caused by multidrug-resistant (MDR) organisms, and no MDR organism colonization;
    • AddedNo intake of probiotics or prebiotics within 1 month before fecal microbiota collection;
    • AddedNo pre-existing chronic gastrointestinal disorders;
    • AddedNo laboratory abnormalities suggestive of active infection, including screening tests such as procalcitonin (PCT), viral hepatitis serology, T-SPOT, syphilis serology, and human immunodeficiency virus (HIV) testing.
    • AddedAble to understand study procedures and voluntarily provide written informed consent; willing and able to adhere to study treatment and follow-up requirements.
    Exclusion criteria
    • RemovedGastrointestinal diseases;Age>60; or Age<10;Probiotics or prebiotics were taken before enrollment
    • AddedPrior history of autologous hematopoietic cell transplantation or allogeneic hematopoietic stem cell transplantation.
    • AddedPrior documented infection with multidrug-resistant (MDR) organisms.
    • AddedPresence of any medical condition that would interfere with study procedures or place the patient at high risk of serious complications, including but not limited to:
    • AddedSevere cardiac dysfunction (left ventricular ejection fraction [LVEF] < 50%);
    • AddedAbnormal hepatic function: serum total bilirubin > 34 µmol/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN);
    • AddedAbnormal renal function: serum creatinine > 130 µmol/L.
    • AddedKnown intolerance to auto-FMT.
    • AddedFailure to satisfy criteria for post-HSCT FMT administration, defined by any of the following:
    • AddedFailure to achieve hematopoietic reconstitution after HSCT;
    • AddedOnset of established acute graft-versus-host disease (aGVHD) prior to auto-FMT;
    • AddedUncontrolled active infection;
    • AddedConcurrent cytomegalovirus (CMV) or Epstein-Barr virus (EBV) reactivation;
    • AddedClinical conditions that preclude tolerance to auto-FMT, including prominent nausea, vomiting, abdominal pain, diarrhea, intestinal obstruction, gastrointestinal bleeding.
    • AddedPregnant or lactating individuals.
    • AddedDementia or altered mental status that impairs the capacity to provide informed consent.
    • AddedAny condition deemed by the investigator to place the patient or study results at unnecessary risk.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Acute Graft-Versus-Host DiseaseNow Cumulative incidence of grade II-IV aGVHDTime frame: 90 days after haploidentical hematopoietic stem cell transplantation → 100 days after HSCT.
    Secondary outcomes 1 edited, 7 added, 1 removed
    What changed in the outcomes
    • EditedoverallOverall survivalTime frame: 90 days after haploidentical hematopoietic stem cell transplantation → 1 year after HSCT.
    • AddedCumulative incidence of grade Ill-IV aGVHDTime frame: 100 days after HSCT.
    • AddedCumulative incidence of chronic graft-versus-host disease(cGVHD)Time frame: 1 year after HSCT.
    • AddedGraft-versus-host disease-free relapse-free survival(GRFS)Time frame: 1 year after HSCT.
    • AddedCumulative incidence of relapseTime frame: 1 year after HSCT.
    • AddedNon-Relapse Mortality(NRM)Time frame: 1 year after HSCT.
    • AddedRelapse-free survival (RFS)Time frame: 1 year after HSCT.
    • AddedGrade 3 or higher adverse eventsTime frame: Up to 100 days.
    • RemovedEvent free survivalTime frame: 90 days after haploidentical hematopoietic stem cell transplantation
    Interventions Added Auto-FMT with Standard Prophylaxis·Drug: Standard Prophylaxis; removed autologous fecal bacteria. Arm changed with auto-FMT→Auto-FMT Group. Arms added: Standard Group; arms removed: empty capsule
    + 6 other changes: identifiers, verification date, description, design details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04745221
Responsible party
Qi Xiao-Fei (Principal Investigator, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Feb 9, 2021
Start date
Aug 27, 2021
Primary completion
Aug 27, 2025
Completion
May 19, 2026
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion